Targeting cancer stem cells: Promises and challenges

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 1, 2016, Pages 38-58

  Kuhlmann, Jan Dominik ^a,b   Hein, Linda ^a   Kurth, Ina ^a   Wimberger, Pauline ^a,b   Dubrovska, Anna ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer stem cells (CSCs); Circulating tumor cells (CTCs); Clonal evolution; CSC plasticity; CSC targeted therapy; Tumor heterogeneity

Indexed keywords

PLERIXAFOR;

ARTICLE; BIOCHEMICAL ANALYSIS; CANCER STEM CELL; CANCER THERAPY; CLONAL EVOLUTION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; DRUG EFFECTS; NEOPLASMS; PATHOLOGY;

HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84947932908     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150716104152     Document Type: Article

References (276)

1. Lohaus, F.; Linge, A.; Tinhofer, I.; Budach, V.; Gkika, E.; Stuschke, M.; Balermpas, P.; Rodel, C.; Avlar, M.; Grosu, A.L.; Abdollahi, A.; Debus, J.; Bayer, C.; Belka, C.; Pigorsch, S.; Combs, S. E.; Monnich, D.; Zips, D.; Von Neubeck, C.; Baretton, G.B.; Lock, S.; Thames, H.D.; Krause, M.; Baumann, M.; Dktk, R.O.G. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group [DKTK-ROG]. Radiother. Oncol., 2014, 113, 317-323.
2. Nowell, P.C. The clonal nature of neoplasia. Cancer Cells, 1989, 1, 29-30.
3. Marjanovic, N.D.; Weinberg, R.A.; Chaffer, C.L. Cell plasticity and heterogeneity in cancer. Clin. Chem., 2013, 59, 168-179.
4. Nowell, P.C. The clonal evolution of tumor cell populations. Science, 1976, 194, 23-28.
5. Burrell, R.A.; Swanton, C. The evolution of the unstable cancer genome. Curr. Opin. Genet. Dev., 2014, 24, 61-67.
6. Burrell, R.A.; Swanton, C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol., 2014, 8, 1095-1111.
7. Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; Bramley, A.H.; Vincent, L.; Costa, C.; MacDonald, D.D.; Jin, D.K.; Shido, K.; Kerns, S.A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J.L.; Altorki, N.; Port, E.R.; Ruggero, D.; Shmelkov, S.V.; Jensen, K.K.; Rafii, S.; Lyden, D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 2005, 438, 820-827.
8. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994, 367, 645-648.
9. Medema, J.P. Cancer stem cells: The challenges ahead. Nat. Cell. Biol., 2013, 15, 338-344.
10. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature, 2007, 445, 111-115.
11. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature, 2004, 432, 396-401.
12. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 3983-3988.
13. Shackleton, M.; Quintana, E.; Fearon, E.R.; Morrison, S.J. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell, 2009, 138, 822-829.
14. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3, 730-737.
15. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res., 2006, 66, 9339-9344.
16. Ahmed, N.; Abubaker, K.; Findlay, J.K. Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. Mol. Aspects Med., 2014, 39, 110-125.
17. Meacham, C.E.; Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. Nature, 2013, 501, 328-337.
18. Stewart, J.M.; Shaw, P.A.; Gedye, C.; Bernardini, M.Q.; Neel, B.G.; Ailles, L.E. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc. Natl. Acad. Sci. USA, 2011, 108, 6468-6473.
19. Kreso, A.; Dick, J.E. Evolution of the cancer stem cell model. Cell Stem Cell, 2014, 14, 275-291.
20. Quintana, E.; Shackleton, M.; Foster, H.R.; Fullen, D.R.; Sabel, M.S.; Johnson, T.M.; Morrison, S.J. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell, 2010, 18, 510-523.
21. Quintana, E.; Shackleton, M.; Sabel, M.S.; Fullen, D.R.; Johnson, T.M.; Morrison, S.J. Efficient tumour formation by single human melanoma cells. Nature, 2008, 456, 593-598.
22. Kalluri, R.; Neilson, E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest., 2003, 112, 1776-1784.
23. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest., 2009, 119, 1420-1428.
24. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2002, 2, 442-454.
25. Bao, S.; Wu, Q.; Sathornsumetee, S.; Hao, Y.; Li, Z.; Hjelmeland, A.B.; Shi, Q.; McLendon, R.E.; Bigner, D.D.; Rich, J.N. Stem celllike glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res., 2006, 66, 7843-7848.
26. Liu, H.; Zhang, X.; Li, J.; Sun, B.; Qian, H.; Yin, Z. The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J. Cancer Res. Clin. Oncol., 2015, 141(2), 189-201.
27. Shih, J.Y.; Tsai, M.F.; Chang, T.H.; Chang, Y.L.; Yuan, A.; Yu, C.J.; Lin, S.B.; Liou, G.Y.; Lee, M.L.; Chen, J.J.; Hong, T.M.; Yang, S.C.; Su, J.L.; Lee, Y.C.; Yang, P.C. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin .Cancer Res., 2005, 11, 8070-8078.
28. Drake, J.M.; Strohbehn, G.; Bair, T.B.; Moreland, J.G.; Henry, M.D. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol. Biol. Cell, 2009, 20, 2207-2217.
29. Smit, M.A.; Geiger, T.R.; Song, J.Y.; Gitelman, I.; Peeper, D.S.A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol. Cell Biol., 2009, 29, 3722-3737.
30. Stoletov, K.; Kato, H.; Zardouzian, E.; Kelber, J.; Yang, J.; Shattil, S.; Klemke, R. Visualizing extravasation dynamics of metastatic tumor cells. J. Cell Sci., 2010, 123, 2332-2341.
31. Ocana, O.H.; Corcoles, R.; Fabra, A.; Moreno-Bueno, G.; Acloque, H.; Vega, S.; Barrallo-Gimeno, A.; Cano, A.; Nieto, M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell, 2012, 22, 709-724.
32. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; Campbell, L.L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 2008, 133, 704-715.
33. Morel, A.P.; Lievre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through epithelialmesenchymal transition. PLoSOne, 2008, 3, e2888.
34. Gupta, P.B.; Fillmore, C.M.; Jiang, G.; Shapira, S.D.; Tao, K.; Kuperwasser, C.; Lander, E.S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 2011, 146, 633-644.
35. Roesch, A.; Fukunaga-Kalabis, M.; Schmidt, E.C.; Zabierowski, S.E.; Brafford, P.A.; Vultur, A.; Basu, D.; Gimotty, P.; Vogt, T.; Herlyn, M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 2010, 141, 583-594.
36. Sharma, S.V.; Lee, D.Y.; Li, B.; Quinlan, M.P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M.A.; Wong, K.K.; Brandstetter, K.; Wittner, B.; Ramaswamy, S.; Classon, M.; Settleman, J. A chromatin-mediated reversible drugtolerant state in cancer cell subpopulations. Cell, 2010, 141, 69-80.
37. Chaffer, C.L.; Brueckmann, I.; Scheel, C.; Kaestli, A.J.; Wiggins, P.A.; Rodrigues, L.O.; Brooks, M.; Reinhardt, F.; Su, Y.; Polyak, K.; Arendt, L.M.; Kuperwasser, C.; Bierie, B.; Weinberg, R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA, 2011, 108, 7950-7955.
38. Theise, N.D.; Harris, R. Postmodern biology: [adult] [stem] cells are plastic, stochastic, complex, and uncertain. Handb. Exp. Pharmacol., 2006, 389-408.
39. Scheel, C.; Weinberg, R.A. Phenotypic plasticity and epithelialmesenchymal transitions in cancer and normal stem cells? Int. J. Cancer., 2011, 129, 2310-2314.
40. Heppner, G.H. Tumor heterogeneity. Cancer Res., 1984, 44, 2259-2265.
41. Bashashati, A.; Ha, G.; Tone, A.; Ding, J.; Prentice, L. M.; Roth, A.; Rosner, J.; Shumansky, K.; Kalloger, S.; Senz, J.; Yang, W.; McConechy, M.; Melnyk, N.; Anglesio, M.; Luk, M.T.; Tse, K.; Zeng, T.; Moore, R.; Zhao, Y.; Marra, M.A.; Gilks, B.; Yip, S.; Huntsman, D.G.; McAlpine, J.N.; Shah, S.P. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol., 2013, 231, 21-34.
42. Campbell, P.J.; Yachida, S.; Mudie, L.J.; Stephens, P.J.; Pleasance, E.D.; Stebbings, L. A.; Morsberger, L.A.; Latimer, C.; McLaren, S.; Lin, M.L.; McBride, D.J.; Varela, I.; Nik-Zainal, S.A.; Leroy, C.; Jia, M.; Menzies, A.; Butler, A.P.; Teague, J.W.; Griffin, C.A.; Burton, J.; Swerdlow, H.; Quail, M.A.; Stratton, M.R.; Iacobuzio-Donahue, C.; Futreal, P.A. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 2010, 467, 1109-1113.
43. Sottoriva, A.; Spiteri, I.; Piccirillo, S.G.; Touloumis, A.; Collins, V.P.; Marioni, J.C.; Curtis, C.; Watts, C.; Tavare, S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA, 2013, 110, 4009-4014.
44. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; Varela, I.; Phillimore, B.; Begum, S.; McDonald, N. Q.; Butler, A.; Jones, D.; Raine, K.; Latimer, C.; Santos, C.R.; Nohadani, M.; Eklund, A.C.; Spencer-Dene, B.; Clark, G.; Pickering, L.; Stamp, G.; Gore, M.; Szallasi, Z.; Downward, J.; Futreal, P.A.; Swanton, C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med., 2012, 366, 883-892.
45. Bateman, C.M.; Colman, S.M.; Chaplin, T.; Young, B.D.; Eden, T.O.; Bhakta, M.; Gratias, E.J.; Van Wering, E.R.; Cazzaniga, G.; Harrison, C.J.; Hain, R.; Ancliff, P.; Ford, A.M.; Kearney, L.; Greaves, M. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood, 2010, 115, 3553-3558.
46. Greaves, M. Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture. Hematol. Am. Soc. Hematol. Educ. Prog., 2009, 3-12.
47. Greaves, M. Cancer stem cells: Back to Darwin? Semin. Cancer Biol., 2010, 20, 65-70.
48. Bird, A. Perceptions of epigenetics. Nature, 2007, 447, 396-398.
49. Belinsky, S.A.; Nikula, K.J.; Palmisano, W.A.; Michels, R.; Saccomanno, G.; Gabrielson, E.; Baylin, S.B.; Herman, J.G. Aberrant methylation of p16[INK4a] is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA, 1998, 95, 11891-11896.
50. Hahn, M.A.; Hahn, T.; Lee, D.H.; Esworthy, R.S.; Kim, B.W.; Riggs, A.D.; Chu, F.F.; Pfeifer, G.P. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res., 2008, 68, 10280-10289.
51. Liu, F.; Killian, J.K.; Yang, M.; Walker, R.L.; Hong, J.A.; Zhang, M.; Davis, S.; Zhang, Y.; Hussain, M.; Xi, S.; Rao, M.; Meltzer, P.A.; Schrump, D.S. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene, 2010, 29, 3650-3964.
52. Ahuja, N.; Li, Q.; Mohan, A.L.; Baylin, S.B.; Issa, J.P. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res., 1998, 58, 5489-5494.
53. Suzuki, H.; Watkins, D.N.; Jair, K.W.; Schuebel, K.E.; Markowitz, S.D.; Chen, W.D.; Pretlow, T.P.; Yang, B.; Akiyama, Y.; Van Engeland, M.; Toyota, M.; Tokino, T.; Hinoda, Y.; Imai, K.; Herman, J.G.; Baylin, S.B. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet., 2004, 36, 417-422.
54. Licchesi, J.D.; Westra, W.H.; Hooker, C.M.; Herman, J.G. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin. Cancer. Res., 2008, 14, 2570-2578.
55. Easwaran, H.; Tsai, H.C.; Baylin, S.B. Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell, 2014, 54, 716-727.
56. Shen, H.; Laird, P.W. Interplay between the cancer genome and epigenome. Cell, 2013, 153, 38-55.
57. You, J.S.; Jones, P.A. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell, 2012, 22, 9-20.
58. Shah, M.Y.; Licht, J.D. DNMT3A mutations in acute myeloid leukemia. Nat. Genet., 2011, 43, 289-290.
59. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S.H.; Ito, S.; Yang, C.; Wang, P.; Xiao, M.T.; Liu, L.X.; Jiang, W.Q.; Liu, J.; Zhang, J.Y.; Wang, B.; Frye, S.; Zhang, Y.; Xu, Y.H.; Lei, Q.Y.; Guan, K. L.; Zhao, S.M.; Xiong, Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutaratedependent dioxygenases. Cancer Cell, 2011, 19, 17-30.
60. Kendal, W.S.; Frost, P. Genomic instability, tumor heterogeneity and progression. Adv. Exp. Med. Biol., 1988, 233, 1-4.
61. Yatabe, Y.; Tavare, S.; Shibata, D. Investigating stem cells in human colon by using methylation patterns. Proc. Natl. Acad. Sci. USA, 2001, 98, 10839-10844.
62. Dalerba, P.; Kalisky, T.; Sahoo, D.; Rajendran, P.S.; Rothenberg, M.E.; Leyrat, A.A.; Sim, S.; Okamoto, J.; Johnston, D.M.; Qian, D.; Zabala, M.; Bueno, J.; Neff, N.F.; Wang, J.; Shelton, A. A.; Visser, B.; Hisamori, S.; Shimono, Y.; Van de Wetering, M.; Clevers, H.; Clarke, M.F.; Quake, S.R. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat. Biotechnol., 2011, 29, 1120-1127.
63. Bernstein, B.E.; Mikkelsen, T.S.; Xie, X.; Kamal, M.; Huebert, D.J.; Cuff, J.; Fry, B.; Meissner, A.; Wernig, M.; Plath, K.; Jaenisch, R.; Wagschal, A.; Feil, R.; Schreiber, S.L.; Lander, E.S.A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell, 2006, 125, 315-326.
64. Easwaran, H.; Johnstone, S.E.; Van Neste, L.; Ohm, J.; Mosbruger, T.; Wang, Q.; Aryee, M.J.; Joyce, P.; Ahuja, N.; Weisenberger, D.; Collisson, E.; Zhu, J.; Yegnasubramanian, S.; Matsui, W.; Baylin, S.B. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genom. Res., 2012, 22, 837-849.
65. Chaffer, C.L.; Marjanovic, N.D.; Lee, T.; Bell, G.; Kleer, C.G.; Reinhardt, F.; D'Alessio, A.C.; Young, R.A.; Weinberg, R.A. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell, 2013, 154, 61-74.
66. Marjanovic, N.D.; Weinberg, R.A.; Chaffer, C.L. Poised with purpose: Cell plasticity enhances tumorigenicity. Cell Cycle, 2013, 12, 2713-2714.
67. Greaves, M.; Maley, C.C. Clonal evolution in cancer. Nature, 2012, 481, 306-313.
68. Cotsarelis, G.; Sun, T.T.; Lavker, R.M. Label-retaining cells reside in the bulge area of pilosebaceous unit: Implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell, 1990, 61, 1329-1337.
69. Arai, F.; Hirao, A.; Ohmura, M.; Sato, H.; Matsuoka, S.; Takubo, K.; Ito, K.; Koh, G.Y.; Suda, T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell, 2004, 118, 149-161.
70. Leis, O.; Eguiara, A.; Lopez-Arribillaga, E.; Alberdi, M.J.; Hernandez-Garcia, S.; Elorriaga, K.; Pandiella, A.; Rezola, R.; Martin, A.G. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene, 2012, 31, 1354-1365.
71. Bertolini, G.; Roz, L.; Perego, P.; Tortoreto, M.; Fontanella, E.; Gatti, L.; Pratesi, G.; Fabbri, A.; Andriani, F.; Tinelli, S.; Roz, E.; Caserini, R.; Lo Vullo, S.; Camerini, T.; Mariani, L.; Delia, D.; Calabro, E.; Pastorino, U.; Sozzi, G. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA, 2009, 106, 16281-16286.
72. Colak, S.; Zimberlin, C.D.; Fessler, E.; Hogdal, L.; Prasetyanti, P.R.; Grandela, C.M.; Letai, A.; Medema, J.P. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ., 2014, 21, 1170-1217.
73. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J. W.; Guba, M.; Bruns, C. J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007, 1, 313-323.
74. Abubaker, K.; Latifi, A.; Luwor, R.; Nazaretian, S.; Zhu, H.; Quinn, M.A.; Thompson, E. W.; Findlay, J.K.; Ahmed, N. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol. Cancer., 2013, 12, 24.
75. Latifi, A.; Abubaker, K.; Castrechini, N.; Ward, A.C.; Liongue, C.; Dobill, F.; Kumar, J.; Thompson, E.W.; Quinn, M.A.; Findlay, J.K.; Ahmed, N. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem., 2011, 112, 2850-2864.
76. Oliver, T.G.; Mercer, K.L.; Sayles, L.C.; Burke, J.R.; Mendus, D.; Lovejoy, K.S.; Cheng, M.H.; Subramanian, A.; Mu, D.; Powers, S.; Crowley, D.; Bronson, R.T.; Whittaker, C.A.; Bhutkar, A.; Lippard, S.J.; Golub, T.; Thomale, J.; Jacks, T.; Sweet-Cordero, E.A. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Gen. Dev., 2010, 24, 837-852.
77. Diehn, M.; Cho, R.W.; Clarke, M.F. Therapeutic implications of the cancer stem cell hypothesis. Semin. Radiat. Oncol., 2009, 19, 78-86.
78. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene, 2010, 29, 4741-4751.
79. Colak, S.; Medema, J.P. Cancer stem cells-important players in tumor therapy resistance. FEBS J, 2014, 281(21), 4779-4777.
80. Gao, M.Q.; Choi, Y P.; Kang, S.; Youn, J.H.; Cho, N.H. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene, 2010, 29, 2672-2680.
81. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K. L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer., 2006, 5, 67.
82. Van Houdt, W.J.; Emmink, B.L.; Pham, T.V.; Piersma, S.R.; Verheem, A.; Vries, R.G.; Fratantoni, S.A.; Pronk, A.; Clevers, H.; Borel Rinkes, I.H.; Jimenez, C.R.; Kranenburg, O. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol. Cell. Proteomic., 2011, 10, M111 011353.
83. De Grouw, E.P.; Raaijmakers, M.H.; Boezeman, J.B.; Van der Reijden, B.A.; Van de Locht, L.T.; de Witte, T.J.; Jansen, J.H.; Raymakers, R.A. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38-cells. Leukemia, 2006, 20, 750-754.
84. Shervington, A.; Lu, C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest., 2008, 26, 535-542.
85. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer., 2002, 2, 48-58.
86. Cojoc, M.; Mabert, K.; Muders, M.H.; Dubrovska, A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Semin. Cancer. Biol., 2015, 31, 16-27.
87. Cojoc, M.; Peitzsch, C.; Kurth, I.; Trautmann, F.; Kunz-Schughart, L.A.; Telegeev, G. D.; Stakhovsky, E.A.; Walker, J.R.; Simin, K.; Lyle, S.; Fuessel, S.; Erdmann, K.; Wirth, M.P.; Krause, M.; Baumann, M.; Dubrovska, A. Aldehyde Dehydrogenase Is Regulated by beta-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. Cancer. Res., 2015, 75, 1482-1494.
88. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I.T.; Zakharenko, S.S.; Gajjar, A.; Davidoff, A.; Gilbertson, R.J.A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11, 69-82.
89. Sprouffske, K.; Athena Aktipis, C.; Radich, J.P.; Carroll, M.; Nedelcu, A.M.; Maley, C.C. An evolutionary explanation for the presence of cancer nonstem cells in neoplasms. Evol. Appl., 2013, 6, 92-101.
90. Mi, J.Q.; Li, J.M.; Shen, Z.X.; Chen, S.J.; Chen, Z. How to manage acute promyelocytic leukemia. Leukemia, 2012, 26, 1743-1751.
91. Woodward, W.A.; Chen, M.S.; Behbod, F.; Alfaro, M.P.; Buchholz, T.A.; Rosen, J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. USA, 2007, 104, 618-623.
92. Takebe, N.; Miele, L.; Harris, P.J.; Jeong, W.; Bando, H.; Kahn, M.; Yang, S.X.; Ivy, S.P. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat. Rev.Clin. Oncol., 2015. 12(8), 445-464.
93. Takebe, N.; Harris, P.J.; Warren, R.Q.; Ivy, S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol., 2011, 8, 97-106.
94. Malhotra, G.K.; Zhao, X.; Band, H.; Band, V. Shared signaling pathways in normal and breast cancer stem cells. J. Carcinog., 2011, 10, 38.
95. Van Amerongen, R.; Nusse, R. Towards an integrated view of Wnt signaling in development. Development, 2009, 136, 3205-3214.
96. Chen, Z.; He, X.; Jia, M.; Liu, Y.; Qu, D.; Wu, D.; Wu, P.; Ni, C.; Zhang, Z.; Ye, J.; Xu, J.; Huang, J. beta-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: A meta-analysis. PLoSOne, 2013, 8, e63854.
97. Zhang, Y.; Liu, B.; Zhao, Q.; Hou, T.; Huang, X. Nuclear localizaiton of beta-catenin is associated with poor survival and chemo-/radioresistance in human cervical squamous cell cancer. Int. J. Clin. Exp. Pathol., 2014, 7, 3908-3917.
98. Schepers, A.G.; Snippert, H.J.; Stange, D.E.; Van den Born, M.; Van Es, J.H.; Van de Wetering, M.; Clevers, H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science, 2012, 337, 730-735.
99. Vermeulen, L.; De Sousa, E.M.F.; van der Heijden, M.; Cameron, K.; de Jong, J.H.; Borovski, T.; Tuynman, J.B.; Todaro, M.; Merz, C.; Rodermond, H.; Sprick, M.R.; Kemper, K.; Richel, D. J.; Stassi, G.; Medema, J.P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell. Biol., 2010, 12, 468-476.
100. Incassati, A.; Chandramouli, A.; Eelkema, R.; Cowin, P. Key signaling nodes in mammary gland development and cancer: Betacatenin. Breast Cancer Res., 2010, 12, 213.
101. Pacheco-Pinedo, E.C.; Durham, A.C.; Stewart, K.M.; Goss, A.M.; Lu, M.M.; Demayo, F.J.; Morrisey, E.E. Wnt/beta-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J. Clin. Invest., 2011, 121, 1935-1945.
102. Yeung, J.; Esposito, M.T.; Gandillet, A.; Zeisig, B.B.; Griessinger, E.; Bonnet, D.; So, C. W. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell, 2010, 18, 606-618.
103. Heidel, F.H.; Bullinger, L.; Feng, Z.; Wang, Z.; Neff, T.A.; Stein, L.; Kalaitzidis, D.; Lane, S.W.; Armstrong, S.A. Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell, 2012, 10, 412-424.
104. Augustin, I.; Goidts, V.; Bongers, A.; Kerr, G.; Vollert, G.; Radlwimmer, B.; Hartmann, C.; Herold-Mende, C.; Reifenberger, G.; Von Deimling, A.; Boutros, M. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO. Mol. Med., 2012, 4, 38-51.
105. Vangipuram, S.D.; Buck, S.A.; Lyman, W.D. Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line. Tumour. Biol., 2012, 33, 2173-2183.
106. Warrier, S.; Bhuvanalakshmi, G.; Arfuso, F.; Rajan, G.; Millward, M.; Dharmarajan, A. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gen. Ther., 2014, 21, 381-388.
107. Chen, B.; Dodge, M.E.; Tang, W.; Lu, J.; Ma, Z.; Fan, C.W.; Wei, S.; Hao, W.; Kilgore, J.; Williams, N.S.; Roth, M.G.; Amatruda, J.F.; Chen, C.; Lum, L. Small molecule-mediated disruption of Wntdependent signaling in tissue regeneration and cancer. Nat. Chem. Biol., 2009, 5, 100-107.
108. Takemaru, K.I.; Moon, R.T. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J. Cell. Biol., 2000, 149, 249-254.
109. Lenz, H.J.; Kahn, M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci., 2014, 105, 1087-1092.
110. Emami, K.H.; Nguyen, C.; Ma, H.; Kim, D.H.; Jeong, K.W.; Eguchi, M.; Moon, R.T.; Teo, J.L.; Kim, H.Y.; Moon, S.H.; Ha, J.R.; Kahn, M. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. USA, 2004, 101, 12682-12687.
111. Takahashi-Yanaga, F.; Kahn, M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin. Cancer Res., 2010, 16, 3153-3162.
112. Horwich, A.; Parker, C.; De Reijke, T.; Kataja, V.; Group, E.G.W. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2013, 24 Suppl 6, vi106-14.
113. Yu, Z.; Pestell, T.G.; Lisanti, M.P.; Pestell, R.G. Cancer stem cells. Int. J. Biochem. Cell .Biol., 2012, 44, 2144-2151.
114. Oishi, N.; Yamashita, T.; Kaneko, S. Molecular biology of liver cancer stem cells. Liver Cancer, 2014, 3, 71-84.
115. Dierks, C.; Beigi, R.; Guo, G.R.; Zirlik, K.; Stegert, M.R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.; Landwerlin, K.; Veelken, H.; Warmuth, M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell, 2008, 14, 238-249.
116. Maun, H.R.; Wen, X.; Lingel, A.; de Sauvage, F.J.; Lazarus, R.A.; Scales, S.J.; Hymowitz, S.G. Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site. J. Biol. Chem., 2010, 285, 26570-26580.
117. Theunissen, JW.; de Sauvage, F.J. Paracrine Hedgehog signaling in cancer. Cancer Res, 2009, 69, 6007-6010.
118. Clement, V.; Sanchez, P.; De Tribolet, N.; Radovanovic, I.; Ruiz i Altaba, A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol., 2007, 17, 165-172.
119. Liu, S.; Dontu, G.; Mantle, I.D.; Patel, S.; Ahn, N.S.; Jackson, K.W.; Suri, P.; Wicha, M.S. Hedgehog signaling and Bmi-1 regulate selfrenewal of normal and malignant human mammary stem cells. Cancer. Res., 2006, 66, 6063-6071.
120. Domingo-Domenech, J.; Vidal, S.J.; Rodriguez-Bravo, V.; Castillo-Martin, M.; Quinn, S.A.; Rodriguez-Barrueco, R.; Bonal, D.M.; Charytonowicz, E.; Gladoun, N.; De la Iglesia-Vicente, J.; Petrylak, D.P.; Benson, M.C.; Silva, J.M.; Cordon-Cardo, C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch-and hedgehog-dependent tumor-initiating cells. Cancer Cell, 2012, 22, 373-388.
121. Cooper, M.K.; Porter, J.A.; Young, K.E.; Beachy, P.A. Teratogenmediated inhibition of target tissue response to Shh signaling. Science, 1998, 280, 1603-1607.
122. Taipale, J.; Chen, J.K.; Cooper, M.K.; Wang, B.; Mann, R.K.; Milenkovic, L.; Scott, M. P.; Beachy, P.A. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature, 2000, 406, 1005-1009.
123. Stanton, B.Z.; Peng, L.F. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol. Biosyst., 2010, 6, 44-54.
124. Bar, E.E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A.L.; DiMeco, F.; Olivi, A.; Eberhart, C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stemlike cancer cells in glioblastoma. Stem Cells, 2007, 25, 2524-2533.
125. Lauth, M.; Bergstrom, A.; Shimokawa, T.; Toftgard, R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA, 2007, 104, 8455-8460.
126. Chen, J.K.; Taipale, J.; Young, K.E.; Maiti, T.; Beachy, P.A. Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA, 2002, 99, 14071-14076.
127. Williams, J.A.; Guicherit, O.M.; Zaharian, B.I.; Xu, Y.; Chai, L.; Wichterle, H.; Kon, C.; Gatchalian, C.; Porter, J.A.; Rubin, L.L.; Wang, F.Y. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc. Natl. Acad. Sci. USA, 2003, 100, 4616-4621.
128. Romer, J.T.; Kimura, H.; Magdaleno, S.; Sasai, K.; Fuller, C.; Baines, H.; Connelly, M.; Stewart, C.F.; Gould, S.; Rubin, L.L.; Curran, T. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1[+/-]p53[-/-] mice. Cancer Cell, 2004, 6, 229-240.
129. Feldmann, G.; Fendrich, V.; McGovern, K.; Bedja, D.; Bisht, S.; Alvarez, H.; Koorstra, J. B.; Habbe, N.; Karikari, C.; Mullendore, M.; Gabrielson, K. L.; Sharma, R.; Matsui, W.; Maitra, A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther., 2008, 7, 2725-2735.
130. Singh, B.N.; Fu, J.; Srivastava, R.K.; Shankar, S. Hedgehog signaling antagonist GDC-0449 [Vismodegib] inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. PLoS. One, 2011, 6, e27306.
131. Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Mackey, H.M.; Lum, B.L.; Darbonne, W.C.; Marsters, J.C., Jr.; De Sauvage, F.J.; Low, J. A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med., 2009, 361, 1164-1172.
132. Delwig, A.; Rand, M.D. Kuz and TACE can activate Notch independent of ligand. Cell Mol. Life Sci., 2008, 65, 2232-2243.
133. Yuan, Z.; Friedmann, D.R.; VanderWielen, B.D.; Collins, K.J.; Kovall, R.A. Characterization of CSL [CBF-1, Su[H], Lag-1] mutants reveals differences in signaling mediated by Notch1 and Notch2. J. Biol. Chem., 2012, 287, 34904-34916.
134. Brou, C.; Logeat, F.; Gupta, N.; Bessia, C.; LeBail, O.; Doedens, J.R.; Cumano, A.; Roux, P.; Black, R.A.; Israel, A.A novel proteolytic cleavage involved in Notch signaling: The role of the disintegrin-metalloprotease TACE. Mol. Cell, 2000, 5, 207-216.
135. Krause, D.S. Regulation of hematopoietic stem cell fate. Oncogene, 2002, 21, 3262-3269.
136. Insan, M.B.; Jaitak, V. New approaches to target cancer stem cells: Current scenario. Mini. Rev. Med. Chem., 2014, 14, 20-34.
137. Takebe, N.; Nguyen, D.; Yang, S.X. Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol. Ther., 2014, 141, 140-149.
138. Pannuti, A.; Foreman, K.; Rizzo, P.; Osipo, C.; Golde, T.; Osborne, B.; Miele, L. Targeting Notch to target cancer stem cells. Clin. Cancer Res., 2010, 16, 3141-3152.
139. Wang, J.; Wakeman, T.P.; Lathia, J.D.; Hjelmeland, A.B.; Wang, X.F.; White, R.R.; Rich, J.N.; Sullenger, B.A. Notch promotes radioresistance of glioma stem cells. Stem Cells, 2010, 28, 17-28.
140. Liu, Y.P.; Yang, C.J.; Huang, M.S.; Yeh, C.T.; Wu, A.T.; Lee, Y.C.; Lai, T.C.; Lee, C.H.; Hsiao, Y. W.; Lu, J.; Shen, C.N.; Lu, P.J.; Hsiao, M. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res., 2013, 73, 406-416.
141. Fischer, M.; Yen, W.C.; Kapoun, A.M.; Wang, M.; O'Young, G.; Lewicki, J.; Gurney, A.; Hoey, T. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res., 2011, 71, 1520-1525.
142. He, S.Z. The resources of the Chinese traditional medicine mabo in Guizhou Province. Zhong Yao Tong Bao, 1986, 11, 14-6.
143. Hassan, K.A.; Wang, L.; Korkaya, H.; Chen, G.; Maillard, I.; Beer, D.G.; Kalemkerian, G.P.; Wicha, M.S. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin. Cancer Res., 2013, 19, 1972-1980.
144. Fonar, Y.; Frank, D. FAK and WNT signaling: The meeting of two pathways in cancer and development. Anticancer Agents Med. Chem., 2011, 11, 600-606.
145. Hu, T.; Li, C. Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol. Cancer, 2010, 9, 236.
146. Hales, E.C.; Taub, J.W.; Matherly, L.H. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: Targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal., 2014, 26, 149-161.
147. Klein, C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer, 2009, 9, 302-312.
148. Klein, G. Foulds' dangerous idea revisited: The multistep development of tumors 40 years later. Adv. Cancer Res., 1998, 72, 1-23.
149. Collins, V.P.; Loeffler, R.K.; Tivey, H. Observations on growth rates of human tumors. Am. J. Roentgenol. Radium Ther. Nucl. Med., 1956, 76, 988-1000.
150. Lianidou, E.S.; Markou, A. Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges. Clin. Chem., 2011, 57, 1242-1255.
151. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.; Hayes, D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med., 2004, 351, 781-791.
152. Hayes, D.F.; Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Miller, M.C.; Matera, J.; Allard, W.J.; Doyle, G.V.; Terstappen, L.W. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res., 2006, 12, 4218-4224.
153. Cohen, S.J.; Punt, C.J.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C.; Doyle, G.V.; Tissing, H.; Terstappen, L.W.; Meropol, N.J. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol., 2008, 26, 3213-3221.
154. De Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C.; Miller, M.C.; Tissing, H.; Doyle, G.V.; Terstappen, L.W.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res., 2008, 14, 6302-6309.
155. Pierga, J.Y.; Hajage, D.; Bachelot, T.; Delaloge, S.; Brain, E.; Campone, M.; Dieras, V.; Rolland, E.; Mignot, L.; Mathiot, C.; Bidard, F.C. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol., 2012, 23, 618-624.
156. Xenidis, N.; Ignatiadis, M.; Apostolaki, S.; Perraki, M.; Kalbakis, K.; Agelaki, S.; Stathopoulos, E.N.; Chlouverakis, G.; Lianidou, E.; Kakolyris, S.; Georgoulias, V.; Mavroudis, D. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol., 2009, 27, 2177-2184.
157. Aktas, B.; Kasimir-Bauer, S.; Heubner, M.; Kimmig, R.; Wimberger, P. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int. J. Gynecol. Cancer, 2011, 21, 822-830.
158. Obermayr, E.; Castillo-Tong, D.C.; Pils, D.; Speiser, P.; Braicu, I.; Van Gorp, T.; Mahner, S.; Sehouli, J.; Vergote, I.; Zeillinger, R. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance--a study of the OVCAD consortium. Gynecol. Oncol., 2013, 128, 15-21.
159. Heitzer, E.; Auer, M.; Gasch, C.; Pichler, M.; Ulz, P.; Hoffmann, E.M.; Lax, S.; Waldispuehl-Geigl, J.; Mauermann, O.; Lackner, C.; Hofler, G.; Eisner, F.; Sill, H.; Samonigg, H.; Pantel, K.; Riethdorf, S.; Bauernhofer, T.; Geigl, J.B.; Speicher, M.R. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res., 2013, 73, 2965-2975.
160. Xenidis, N.; Perraki, M.; Kafousi, M.; Apostolaki, S.; Bolonaki, I.; Stathopoulou, A.; Kalbakis, K.; Androulakis, N.; Kouroussis, C.; Pallis, T.; Christophylakis, C.; Argyraki, K.; Lianidou, E.S.; Stathopoulos, S.; Georgoulias, V.; Mavroudis, D. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNApositive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol., 2006, 24, 3756-3762.
161. Andreopoulou, E.; Yang, L.Y.; Rangel, K.M.; Reuben, J.M.; Hsu, L.; Krishnamurthy, S.; Valero, V.; Fritsche, H.A.; Cristofanilli, M. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int. J. Cancer, 2012, 130, 1590-1597.
162. Kuhlmann, J.D.; Wimberger, P.; Bankfalvi, A.; Keller, T.; Scholer, S.; Aktas, B.; Buderath, P.; Hauch, S.; Otterbach, F.; Kimmig, R.; Kasimir-Bauer, S. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin. Chem., 2014, 60, 1282-1289.
163. Vishnoi, M.; Mishra, D.K.; Thrall, M.J.; Kurie, J.M.; Kim, M.P. Circulating tumor cells from a 4-dimensional lung cancer model are resistant to cisplatin. J. Thorac. Cardiovasc. Surg., 2014, 148, 1056-1064.
164. Pavese, J.M.; Bergan, R.C. Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. Cancer Lett., 2014, 352, 179-186.
165. Baccelli, I.; Schneeweiss, A.; Riethdorf, S.; Stenzinger, A.; Schillert, A.; Vogel, V.; Klein, C.; Saini, M.; Bauerle, T.; Wallwiener, M.; Holland-Letz, T.; Hofner, T.; Sprick, M.; Scharpff, M.; Marme, F.; Sinn, H.P.; Pantel, K.; Weichert, W.; Trumpp, A. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol., 2013, 31, 539-544.
166. Rossi, E.; Basso, U.; Celadin, R.; Zilio, F.; Pucciarelli, S.; Aieta, M.; Barile, C.; Sava, T.; Bonciarelli, G.; Tumolo, S.; Ghiotto, C.; Magro, C.; Jirillo, A.; Indraccolo, S.; Amadori, A.; Zamarchi, R. M30 neoepitope expression in epithelial cancer: Quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin. Cancer Res., 2010, 16, 5233-5243.
167. Khoja, L.; Backen, A.; Sloane, R.; Menasce, L.; Ryder, D.; Krebs, M.; Board, R.; Clack, G.; Hughes, A.; Blackhall, F.; Valle, J. W.; Dive, C. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br. J. Cancer, 2012, 106, 508-516.
168. Li, M.; Zhang, B.; Zhang, Z.; Liu, X.; Qi, X.; Zhao, J.; Jiang, Y.; Zhai, H.; Ji, Y.; Luo, D. Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. Biomed. Res. Int., 2014, 2014, 981261.
169. Swaminathan, S.K.; Roger, E.; Toti, U.; Niu, L.; Ohlfest, J.R.; Panyam, J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J. Cont. Rel., 2013, 171, 280-287.
170. Rana, K.; Liesveld, J.L.; King, M.R. Delivery of apoptotic signal to rolling cancer cells: A novel biomimetic technique using immobilized TRAIL and E-selectin. Biotechnol. Bioeng., 2009, 102, 1692-1702.
171. Huang, Z.; King, M.R. An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation. Gene Ther., 2009, 16, 1271-1282.
172. Hughes, A.D.; King, M.R. Nanobiotechnology for the capture and manipulation of circulating tumor cells. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol., 2012, 4, 291-309.
173. Zhang, L.; Sun, H.; Zhao, F.; Lu, P.; Ge, C.; Li, H.; Hou, H.; Yan, M.; Chen, T.; Jiang, G.; Xie, H.; Cui, Y.; Huang, X.; Fan, J.; Yao, M.; Li, J. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res., 2012, 72, 4276-4285.
174. Scarberry, K.E.; Dickerson, E.B.; McDonald, J.F.; Zhang, Z.J. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J. Am. Chem. Soc., 2008, 130, 10258-10262.
175. Scarberry, K.E.; Dickerson, E.B.; Zhang, Z.J.; Benigno, B.B.; McDonald, J.F. Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. Nanomedicine, 2010, 6, 399-408.
176. Scarberry, K.E.; Mezencev, R.; McDonald, J.F. Targeted removal of migratory tumor cells by functionalized magnetic nanoparticles impedes metastasis and tumor progression. Nanomedicine [Lond], 2011, 6, 69-78.
177. Schofield, R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells, 1978, 4, 7-25.
178. Faurobert, E.; Bouin, A.P.; Albiges-Rizo, C. Microenvironment, tumor cell plasticity, and cancer. Curr. Opin. Oncol., 2015, 27, 64-70.
179. Plaks, V.; Kong, N.; Werb, Z. The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell, 2015, 16, 225-238.
180. Folkins, C.; Man, S.; Xu, P.; Shaked, Y.; Hicklin, D.J.; Kerbel, R.S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res., 2007, 67, 3560-3564.
181. Burkhardt, J.K.; Hofstetter, C.P.; Santillan, A.; Shin, B.J.; Foley, C.P.; Ballon, D.J.; Pierre Gobin, Y.; Boockvar, J.A. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intraarterial delivery of bevacizumab: from bedside to bench. J. Clin. Neurosci., 2012, 19, 1568-1572.
182. Espinoza, I.; Miele, L. Notch inhibitors for cancer treatment. Pharmacol. Ther., 2013, 139, 95-110.
183. LaBarge, M.A. The difficulty of targeting cancer stem cell niches. Clin. Cancer Res., 2010, 16, 3121-3129.
184. Matsunaga, T.; Takemoto, N.; Sato, T.; Takimoto, R.; Tanaka, I.; Fujimi, A.; Akiyama, T.; Kuroda, H.; Kawano, Y.; Kobune, M.; Kato, J.; Hirayama, Y.; Sakamaki, S.; Kohda, K.; Miyake, K.; Niitsu, Y. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med., 2003, 9, 1158-1165.
185. Jin, L.; Hope, K.J.; Zhai, Q.; Smadja-Joffe, F.; Dick, J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med., 2006, 12, 1167-1174.
186. Cojoc, M.; Peitzsch, C.; Trautmann, F.; Polishchuk, L.; Telegeev, G.D.; Dubrovska, A. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco. Targets Ther., 2013, 6, 1347-1361.
187. Burger, M.; Hartmann, T.; Krome, M.; Rawluk, J.; Tamamura, H.; Fujii, N.; Kipps, T.J.; Burger, J.A. Small peptide inhibitors of the CXCR4 chemokine receptor [CD184] antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood, 2005, 106, 1824-1830.
188. Peitzsch, C.; Perrin, R.; Hill, R.P.; Dubrovska, A.; Kurth, I. Hypoxia as a biomarker for radioresistant cancer stem cells. Int. J. Radiat. Biol., 2014, 90, 636-652.
189. Hill, R.P.; Marie-Egyptienne, D.T.; Hedley, D.W. Cancer stem cells, hypoxia and metastasis. Semin. Radiat. Oncol., 2009, 19, 106-11.
190. Jeter, C.R.; Liu, B.; Liu, X.; Chen, X.; Liu, C.; Calhoun-Davis, T.; Repass, J.; Zaehres, H.; Shen, J.J.; Tang, D.G. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene, 2011, 30, 3833-3845.
191. Lee, K.; Zhang, H.; Qian, D.Z.; Rey, S.; Liu, J.O.; Semenza, G.L. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. USA, 2009, 106, 17910-17915.
192. Baumann, F.; Leukel, P.; Doerfelt, A.; Beier, C.P.; Dettmer, K.; Oefner, P.J.; Kastenberger, M.; Kreutz, M.; Nickl-Jockschat, T.; Bogdahn, U.; Bosserhoff, A.K.; Hau, P. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro. Oncol., 2009, 11, 368-380.
193. Martinez-Zaguilan, R.; Seftor, E.A.; Seftor, R.E.; Chu, Y.W.; Gillies, R.J.; Hendrix, M.J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis, 1996, 14, 176-186.
194. Robey, I.F.; Baggett, B.K.; Kirkpatrick, N.D.; Roe, D.J.; Dosescu, J.; Sloane, B.F.; Hashim, A.I.; Morse, D.L.; Raghunand, N.; Gatenby, R.A.; Gillies, R.J. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res., 2009, 69, 2260-2268.
195. Chiche, J.; Ilc, K.; Laferriere, J.; Trottier, E.; Dayan, F.; Mazure, N.M.; Brahimi-Horn, M.C.; Pouyssegur, J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res., 2009, 69, 358-368.
196. Supuran, C.T. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med. Chem., 2011, 3, 1165-1180.
197. Lee, E.S.; Gao, Z.; Kim, D.; Park, K.; Kwon, I.C.; Bae, Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pH[e] specific TAT exposure and multidrug resistance. J. Cont. Rel., 2008, 129, 228-236.
198. Koppenol, W.H.; Bounds, P.L.; Dang, C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer, 2011, 11, 325-337.
199. Warburg, O. On respiratory impairment in cancer cells. Science, 1956, 124, 269-270.
200. Rabinowitz, J.D.; White, E. Autophagy and metabolism. Science, 2010, 330, 1344-1348.
201. Kubisch, J.; Turei, D.; Foldvari-Nagy, L.; Dunai, Z.A.; Zsakai, L.; Varga, M.; Vellai, T.; Csermely, P.; Korcsmaros, T. Complex regulation of autophagy in cancer-integrated approaches to discover the networks that hold a double-edged sword. Semin. Cancer Biol., 2013, 23, 252-261.
202. Chen, N.; Karantza, V. Autophagy as a therapeutic target in cancer. Cancer Biol. Ther., 2011, 11, 157-168.
203. Ewald, B.; Sampath, D.; Plunkett, W. Nucleoside analogs: Molecular mechanisms signaling cell death. Oncogene, 2008, 27, 6522-6537.
204. Peitzsch, C.; Kurth, I.; Kunz-Schughart, L.; Baumann, M.; Dubrovska, A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother. Oncol., 2013, 108, 378-387.
205. Varum, S.; Rodrigues, A.S.; Moura, M.B.; Momcilovic, O.; Easley, C.A.t.; Ramalho-Santos, J.; Van Houten, B.; Schatten, G. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS. One, 2011, 6, e20914.
206. Palorini, R.; Votta, G.; Balestrieri, C.; Monestiroli, A.; Olivieri, S.; Vento, R.; Chiaradonna, F. Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. J. Cell Biochem., 2014, 115, 368-379.
207. Koukourakis, M.I.; Giatromanolaki, A.; Simopoulos, C.; Polychronidis, A.; Sivridis, E. Lactate dehydrogenase 5 [LDH5] relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin. Exp. Metastasis, 2005, 22, 25-30.
208. Xie, H.; Hanai, J.; Ren, J.G.; Kats, L.; Burgess, K.; Bhargava, P.; Signoretti, S.; Billiard, J.; Duffy, K.J.; Grant, A.; Wang, X.; Lorkiewicz, P.K.; Schatzman, S.; Bousamra, M., 2nd; Lane, A.N.; Higashi, R.M.; Fan, T.W.; Pandolfi, P.P.; Sukhatme, V.P.; Seth, P. Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumorinitiating cells. Cell Metab., 2014, 19, 795-809.
209. Thornburg, J.M.; Nelson, K.K.; Clem, B.F.; Lane, A.N.; Arumugam, S.; Simmons, A.; Eaton, J.W.; Telang, S.; Chesney, J. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res., 2008, 10, R84.
210. Le, A.; Cooper, C.R.; Gouw, A.M.; Dinavahi, R.; Maitra, A.; Deck, L.M.; Royer, R.E.; Vander Jagt, D.L.; Semenza, G.L.; Dang, C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci USA, 2010, 107, 2037-2042.
211. Michelakis, E.D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T.L.; Mackey, J.R.; Fulton, D.; Abdulkarim, B.; McMurtry, M.S.; Petruk, K.C. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med., 2010, 2, 31ra34.
212. Dong, C.; Yuan, T.; Wu, Y.; Wang, Y.; Fan, T. W.; Miriyala, S.; Lin, Y.; Yao, J.; Shi, J.; Kang, T.; Lorkiewicz, P.; St Clair, D.; Hung, M.C.; Evers, B.M.; Zhou, B.P. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell, 2013, 23, 316-331.
213. Feng, W.; Gentles, A.; Nair, R.V.; Huang, M.; Lin, Y.; Lee, C.Y.; Cai, S.; Scheeren, F.A.; Kuo, A.H.; Diehn, M. Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells, 2014, 32, 1734-1745.
214. Hirsch, H.A.; Iliopoulos, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res., 2009, 69, 7507-7511.
215. Baumann, M.; Krause, M.; Thames, H.; Trott, K.; Zips, D. Cancer stem cells and radiotherapy. Int. J. Radiat. Biol., 2009, 85, 391-402.
216. Butof, R.; Dubrovska, A.; Baumann, M. Clinical perspectives of cancer stem cell research in radiation oncology. Radiother. Oncol., 2013, 108, 388-396.
217. Dubrovska, A.; Elliott, J.; Salamone, R.J.; Kim, S.; Aimone, L.J.; Walker, J.R.; Watson, J.; Sauveur-Michel, M.; Garcia-Echeverria, C.; Cho, C.Y.; Reddy, V.A.; Schultz, P.G. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin. Cancer Res., 2010, 16, 5692-5702.
218. Dubrovska, A.; Kim, S.; Salamone, R.J.; Walker, J.R.; Maira, S.M.; Garcia-Echeverria, C.; Schultz, P.G.; Reddy, V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA, 2009, 106, 268-273.
219. Cojoc, M.; Mabert, K.; Muders, M.H.; Dubrovska, A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Semin. Cancer Biol., 2014.
220. Baccelli, I.; Trumpp, A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol., 2012, 198, 281-293.
221. Blanco, R.; Iwakawa, R.; Tang, M.; Kohno, T.; Angulo, B.; Pio, R.; Montuenga, L. M.; Minna, J.D.; Yokota, J.; Sanchez-Cespedes, M. A gene-alteration profile of human lung cancer cell lines. Hum. Mutat., 2009, 30, 1199-1206.
222. Gayet, J.; Zhou, X.P.; Duval, A.; Rolland, S.; Hoang, J.M.; Cottu, P.; Hamelin, R. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene, 2001, 20, 5025-5032.
223. Dontu, G.; Abdallah, W.M.; Foley, J.M.; Jackson, K.W.; Clarke, M.F.; Kawamura, M.J.; Wicha, M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Gen. Dev., 2003, 17, 1253-1270.
224. Reynolds, B.A.; Weiss, S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol., 1996, 175, 1-13.
225. Pastrana, E.; Silva-Vargas, V.; Doetsch, F. Eyes wide open: A critical review of sphere-formation as an assay for stem cells. Cell Stem Cell, 2011, 8, 486-498.
226. Grinshtein, N.; Datti, A.; Fujitani, M.; Uehling, D.; Prakesch, M.; Isaac, M.; Irwin, M. S.; Wrana, J. L.; Al-Awar, R.; Kaplan, D.R. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res., 2011, 71, 1385-1395.
227. Foong CS, S.E., Brooks H.B, Campbell R.M, Ang B.T, Chong Y.K, Tang C. Glioma-propagating cells as an in vitro screening platform: PLK1 as a case study. J. Biomol. Screen, 2012, 17, 1136-1150.
228. Hu K, L.J.; Fotovati, A.; Dunn, S.E. Small interfering RNA library screen identified polo-like kinase-1 [PLK1] as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res., 2012, 14, R22.
229. Francescangeli, F.P.M.; Signore, M.; Federici, G.; Di Franco, S.; Pagliuca, A.; Baiocchi, M.; Biffoni, M.; Ricci Vitiani, L.; Todaro, M.; De Maria, R.; Zeuner, A. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells, 2012, 30, 1819-1830.
230. Calvet, C.Y.; Andre, F.M.; Mir, L.M. The culture of cancer cell lines as tumorspheres does not systematically result in cancer stem cell enrichment. PLoSOne, 2014, 9, e89644.
231. Nieto, M.A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science, 2013, 342, 1234850.
232. Steinestel, K.; Eder, S.; Schrader, A.J.; Steinestel, J. Clinical significance of epithelial-mesenchymal transition. Clin. Transl. Med., 2014, 3, 17.
233. Puisieux, A.; Brabletz, T.; Caramel, J. Oncogenic roles of EMTinducing transcription factors. Nat. Cell Biol., 2014, 16, 488-494.
234. Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 2009, 138, 645-659.
235. Naujokat, C.; Steinhart, R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol., 2012, 2012, 950658.
236. Nishi, M.; Akutsu, H.; Kudoh, A.; Kimura, H.; Yamamoto, N.; Umezawa, A.; Lee, S.W.; Ryo, A. Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell. Oncotarget, 2014, 5, 8665-8680.
237. Oshima, N.; Yamada, Y.; Nagayama, S.; Kawada, K.; Hasegawa, S.; Okabe, H.; Sakai, Y.; Aoi, T. Induction of cancer stem cell properties in colon cancer cells by defined factors. PLoSOne, 2014, 9, e101735.
238. Nishi, M.; Sakai, Y.; Akutsu, H.; Nagashima, Y.; Quinn, G.; Masui, S.; Kimura, H.; Perrem, K.; Umezawa, A.; Yamamoto, N.; Lee, S. W.; Ryo, A. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene, 2014, 33, 643-652.
239. McDermott, S.P.; Eppert, K.; Notta, F.; Isaac, M.; Datti, A.; Al-Awar, R.; Wrana, J.; Minden, M.D.; Dick, J.E. A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. Blood, 2012, 119, 1200-1207.
240. Sachlos, E.; Risueno, R. M.; Laronde, S.; Shapovalova, Z.; Lee, J. H.; Russell, J.; Malig, M.; McNicol, J.D.; Fiebig-Comyn, A.; Graham, M.; Levadoux-Martin, M.; Lee, J.B.; Giacomelli, A.O.; Hassell, J.A.; Fischer-Russell, D.; Trus, M.R.; Foley, R.; Leber, B.; Xenocostas, A.; Brown, E.D.; Collins, T.J.; Bhatia, M. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell, 2012, 149, 1284-1297.
241. Diamandis, P.; Wildenhain, J.; Clarke, I.D.; Sacher, A.G.; Graham, J.; Bellows, D.S.; Ling, E.K.; Ward, R.J.; Jamieson, L.G.; Tyers, M.; Dirks, P.B. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat. Chem. Biol., 2007, 3, 268-273.
242. Ke, X.Y.; Lin Ng, V.W.; Gao, S.J.; Tong, Y.W.; Hedrick, J.L.; Yang, Y.Y. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials, 2014, 35, 1096-1108.
243. Mu, J.; Xu, H.; Yang, Y.; Huang, W.; Xiao, J.; Li, M.; Tan, Z.; Ding, Q.; Zhang, L.; Lu, J.; Wu, X.; Liu, Y. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol. Rep., 2014, 31, 2107-2114.
244. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A.R.; Herrmann, H.; Sison, E.A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M.J.; Johns, C.; Chicas, A.; Mulloy, J.C.; Kogan, S.C.; Brown, P.; Valent, P.; Bradner, J.E.; Lowe, S.W.; Vakoc, C.R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011, 478, 524-528.
245. Herrmann, H.; Blatt, K.; Shi, J.; Gleixner, K.V.; Cerny-Reiterer, S.; Mullauer, L.; Vakoc, C.R.; Sperr, W. R.; Horny, H.P.; Bradner, J.E.; Zuber, J.; Valent, P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia AML. Oncotarget, 2012, 3, 1588-1599.
246. Kim, J.; Woo, A.J.; Chu, J.; Snow, J.W.; Fujiwara, Y.; Kim, C.G.; Cantor, A.B.; Orkin, S.H. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell, 2010, 143, 313-324.
247. Roderick, J.E.; Tesell, J.; Shultz, L.D.; Brehm, M.A.; Greiner, D.L.; Harris, M.H.; Silverman, L.B.; Sallan, S.E.; Gutierrez, A.; Look, A.T.; Qi, J.; Bradner, J.E.; Kelliher, M.A. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood, 2014, 123, 1040-1050.
248. Venkataraman, S.; Alimova, I.; Balakrishnan, I.; Harris, P.; Birks, D.K.; Griesinger, A.; Amani, V.; Cristiano, B.; Remke, M.; Taylor, M.D.; Handler, M.; Foreman, N.K.; Vibhakar, R. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget, 2014, 5, 2355-2371.
249. Hassane, D.C.; Guzman, M.L.; Corbett, C.; Li, X.; Abboud, R.; Young, F.; Liesveld, J.L.; Carroll, M.; Jordan, C.T. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood, 2008, 111, 5654-5662.
250. Guzman, M.L.; Swiderski, C.F.; Howard, D.S.; Grimes, B.A.; Rossi, R.M.; Szilvassy, S.J.; Jordan, C.T. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA, 2002, 99, 16220-16225.
251. Guzman, M.L.; Rossi, R.M.; Karnischky, L.; Li, X.; Peterson, D.R.; Howard, D.S.; Jordan, C.T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood, 2005, 105, 4163-4169.
252. Konantz, M.; Balci, T.B.; Hartwig, U.F.; Dellaire, G.; Andre, M.C.; Berman, J.N.; Lengerke, C. Zebrafish xenografts as a tool for in vivo studies on human cancer. Ann. N. Y. Acad. Sci., 2012, 1266, 124-137.
253. Zhang, B.; Shimada, Y.; Kuroyanagi, J.; Umemoto, N.; Nishimura, Y.; Tanaka, T. Quantitative phenotyping-based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantation. PLoS. One, 2014, 9, e85439.
254. Zhang, B.; Shimada, Y.; Kuroyanagi, J.; Nishimura, Y.; Umemoto, N.; Nomoto, T.; Shintou, T.; Miyazaki, T.; Tanaka, T. Zebrafish xenotransplantation model for cancer stem-like cell study and highthroughput screening of inhibitors. Tumour Biol., 2014, 35(12), 11861-11869.
255. Veinotte, C.J.; Dellaire, G.; Berman, J.N. Hooking the big one: The potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis. Model Mech., 2014, 7, 745-754.
256. Magee, J.A.; Piskounova, E.; Morrison, S.J. Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell, 2012, 21, 283-296.
257. Howe, K.; Clark, M.D.; Torroja, C.F.; Torrance, J.; Berthelot, C.; Muffato, M.; Collins, J. E.; Humphray, S.; McLaren, K.; Matthews, L.; McLaren, S.; Sealy, I.; Caccamo, M.; Churcher, C.; Scott, C.; Barrett, J.C.; Koch, R.; Rauch, G.J.; White, S.; Chow, W.; Kilian, B.; Quintais, L.T.; Guerra-Assuncao, J.A.; Zhou, Y.; Gu, Y.; Yen, J.; Vogel, J.H.; Eyre, T.; Redmond, S.; Banerjee, R.; Chi, J.; Fu, B.; Langley, E.; Maguire, S.F.; Laird, G.K.; Lloyd, D.; Kenyon, E.; Donaldson, S.; Sehra, H.; Almeida-King, J.; Loveland, J.; Trevanion, S.; Jones, M.; Quail, M.; Willey, D.; Hunt, A.; Burton, J.; Sims, S.; McLay, K.; Plumb, B.; Davis, J.; Clee, C.; Oliver, K.; Clark, R.; Riddle, C.; Elliot, D.; Threadgold, G.; Harden, G.; Ware, D.; Begum, S.; Mortimore, B.; Kerry, G.; Heath, P.; Phillimore, B.; Tracey, A.; Corby, N.; Dunn, M.; Johnson, C.; Wood, J.; Clark, S.; Pelan, S.; Griffiths, G.; Smith, M.; Glithero, R.; Howden, P.; Barker, N.; Lloyd, C.; Stevens, C.; Harley, J.; Holt, K.; Panagiotidis, G.; Lovell, J.; Beasley, H.; Henderson, C.; Gordon, D.; Auger, K.; Wright, D.; Collins, J.; Raisen, C.; Dyer, L.; Leung, K.; Robertson, L.; Ambridge, K.; Leongamornlert, D.; McGuire, S.; Gilderthorp, R.; Griffiths, C.; Manthravadi, D.; Nichol, S.; Barker, G. The zebrafish reference genome sequence and its relationship to the human genome. Nature, 2013, 496, 498-503.
258. Marshall, D.J.; Gaulton, G.N. The role of the immune response in MULV-induced lymphomagenesis. Leukemia, 1996, 10, 1860-1866.
259. Liu, S.H.; Zhang, M.; Zhang, W.G. Strategies of antigen-specific Tcell-based immunotherapy for cancer. Cancer Biother. Radiopharm., 2005, 20, 491-501.
260. Cekanova, M.; Rathore, K. Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des. Devel. Ther., 2014, 8, 1911-1922.
261. Johnson, J.I.; Decker, S.; Zaharevitz, D.; Rubinstein, L.V.; Venditti, J.M.; Schepartz, S.; Kalyandrug, S.; Christian, M.; Arbuck, S.; Hollingshead, M.; Sausville, E.A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer, 2001, 84, 1424-1431.
262. Kerbel, R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: Better than commonly perceived-but they can be improved. Cancer Biol. Ther., 2003, 2, S134-S139.
263. Richmond, A.; Su, Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis. Model Mech., 2008, 1, 78-82.
264. Chen, J.; Li, Y.; Yu, T.S.; McKay, R.M.; Burns, D.K.; Kernie, S.G.; Parada, L.F.A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 2012, 488, 522-526.
265. Driessens, G.; Beck, B.; Caauwe, A.; Simons, B.D.; Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature, 2012, 488, 527-530.
266. Gargiulo, G.; Cesaroni, M.; Serresi, M.; De Vries, N.; Hulsman, D.; Bruggeman, S.W.; Lancini, C.; Van Lohuizen, M. In vivo RNAi screen for BMI1 targets identifies TGF-beta/BMP-ER stress pathways as key regulators of neural-and malignant glioma-stem cell homeostasis. Cancer Cell, 2013, 23, 660-676.
267. Yan, C.; Jamaluddin, M.S.; Aggarwal, B.; Myers, J.; Boyd, D.D. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol. Cancer Ther., 2005, 4, 233-241.
268. Piyanuch, R.; Sukhthankar, M.; Wandee, G.; Baek, S.J. Berberine, A natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Lett., 2007, 258, 230-240.
269. Cho, K.N.; Sukhthankar, M.; Lee, S.H.; Yoon, J.H.; Baek, S.J. Green tea catechin [-]-epicatechin gallate induces tumour suppressor protein ATF3 via EGR-1 activation. Eur. J. Cancer, 2007, 43, 2404-2412.
270. Tian, Z.; An, N.; Zhou, B.; Xiao, P.; Kohane, I.S.; Wu, E. Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells. Cancer Chemother. Pharmacol., 2009, 63, 1131-1139.
271. Zhang, Y.; Wang, S.X.; Ma, J.W.; Li, H.Y.; Ye, J.C.; Xie, S.M.; Du, B.; Zhong, X.Y. EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of Pglycoprotein inhibition. J. Neurooncol., 2015. 121(1), 41-52.
272. Li, H.; Guo, L.; Jie, S.; Liu, W.; Zhu, J.; Du, W.; Fan, L.; Wang, X.; Fu, B.; Huang, S. Berberine inhibits SDF-1-induced AML cells and leukemic stem cells migration via regulation of SDF-1 level in bone marrow stromal cells. Biomed. Pharmacother., 2008, 62, 573-578.
273. Zang, S.; Liu, T.; Shi, J.; Qiao, L. Curcumin: A promising agent targeting cancer stem cells. Anticanc. Agen. Med. Chem., 2014, 14, 787-792.
274. Feng, X.; Zhou, Q.; Liu, C.; Tao, M.L. Drug screening study using glioma stem-like cells. Mol. Med. Rep., 2012, 6, 1117-1120.
275. Castro Nava, A.; Cojoc, M.; Peitzsch, C.; Cirillo, G.; Kurth, I.; Fuessel, S.; Erdmann, K.; Kunhardt, D.; Vittorio, O.; Hampel, S.; Dubrovska, A. Development of novel radio-chemotherapy approaches targeting prostate tumor progenitor cells using nanohybrids. Int. J. Cancer., 2015. 137(10), 2492-2503.
276. Hu, Y.; Smyth, G.K. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods, 2009, 347, 70-78.